Siemens adds to syngo Oncology suite
Siemens Healthcare unveiled a host of MR Oncology Applications including syngo TimCT Oncology, syngo Tissue 4D, new breast MRI coils and syngo GRACE @ 3T quantitative breast MR spectroscopy at the 2008 RSNA conference in Chicago.
The syngo TimCT Oncology joins Siemens' Oncology Solutions and offers continuous table movement for extended field of view imaging and comprehensive staging for increased workflow. For example, a pelvic exam can be completed in as little as 20 minutes. syngo TimCT Oncology reduces the need for rescheduling multiple exams on other modalities by offering one complete exam on one system.
The syngo Tissue 4D offers evaluation with quantification of tumor tissues in organs, such as the prostate and liver. This solution offers two evaluation workflows: standard and Pharmacokinetic modeling (PKM). PKM quantifies the contrast uptake and can be used for oncology workflow and follow-up studies.
Siemens showed Biospy & Imaging and Advanced Imaging (AI) coils, manufactured by Noras and Rapid, respectively on 1.5T Tim systems and 3T Tim systems. The modular and versatile concept makes it possible to customize the coils; one frame comes with different inserts for imaging and biopsy. The AI breast coil will be available with 16 RF channels for high acceleration factors and advanced imaging. The second new breast coil for imaging and biopsy on 1.5T Tim systems is the Sentinelle Vanguard for Siemens. The coil is designed with variable coil geometry that allows the coil to accommodate a wide range of patient sizes, increases patient comfort, and increases signal-to-noise ratio to deliver high quality images with 8 RF channels.
Siemens also introduced quantitative MR breast spectroscopy—syngo Grace @ 3T. The system monitors choline, acting as a biomarker, and provides valuable information on the biochemical composition of breast lesions. By checking relative choline concentration during therapy, the monitoring of treatment efficiency is more reliable, which increases quality and reduces costs of disease management. Preliminary results show that detection of choline signal in breast tumors correlates with breast cancer, confirmed by biopsy, ultrasound and/or mammography.
The syngo TimCT Oncology joins Siemens' Oncology Solutions and offers continuous table movement for extended field of view imaging and comprehensive staging for increased workflow. For example, a pelvic exam can be completed in as little as 20 minutes. syngo TimCT Oncology reduces the need for rescheduling multiple exams on other modalities by offering one complete exam on one system.
The syngo Tissue 4D offers evaluation with quantification of tumor tissues in organs, such as the prostate and liver. This solution offers two evaluation workflows: standard and Pharmacokinetic modeling (PKM). PKM quantifies the contrast uptake and can be used for oncology workflow and follow-up studies.
Siemens showed Biospy & Imaging and Advanced Imaging (AI) coils, manufactured by Noras and Rapid, respectively on 1.5T Tim systems and 3T Tim systems. The modular and versatile concept makes it possible to customize the coils; one frame comes with different inserts for imaging and biopsy. The AI breast coil will be available with 16 RF channels for high acceleration factors and advanced imaging. The second new breast coil for imaging and biopsy on 1.5T Tim systems is the Sentinelle Vanguard for Siemens. The coil is designed with variable coil geometry that allows the coil to accommodate a wide range of patient sizes, increases patient comfort, and increases signal-to-noise ratio to deliver high quality images with 8 RF channels.
Siemens also introduced quantitative MR breast spectroscopy—syngo Grace @ 3T. The system monitors choline, acting as a biomarker, and provides valuable information on the biochemical composition of breast lesions. By checking relative choline concentration during therapy, the monitoring of treatment efficiency is more reliable, which increases quality and reduces costs of disease management. Preliminary results show that detection of choline signal in breast tumors correlates with breast cancer, confirmed by biopsy, ultrasound and/or mammography.